脑机接口概念日内震荡走高，翔宇医疗涨超10%，爱朋医疗、创新医疗、倍益康、伟思医疗、三博脑科 等快速跟涨。消息面上，苹果公司正在与脑机接口公司合作开发"使用大脑信号操纵苹果设备"的技术标 准。周一公布的一段展示视频，首次演示了这项技术的进展。演示视频显示，一位渐冻症患者通过脑机 设备成功实现用意念控制iPad操作，并展现应用脑机接口使用"快捷指令"等操作。 ...

| 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 873690 | 捷众科技 | 1 | 18.62 | 20.45亿 | 74.98 | | 301357 | 北方长龙 | 1 | 12.31 | 123亿 | 287.82 | | 601606 | 长城车工 | 1 | 9.99 | 309亿 | 263.18 | | 000901 | 航天科技 | 4 + | 9.62 | 116亿 | 32.91 | | 836247 | 华密新材 | 1 | 8.72 | 36.16亿 | 44.40 | | 688788 | 科思科技 | 1 | 8.62 | 124亿 | 270.39 | | 300490 | 华自科技 | | 8.62 | 41.70亿 | 32.74 | | 002046 | 国机精工 | 1 | 8.44 | 123亿 | 66.42 | | 688626 | 翔宇医疗 | | 8.36 | 81.28亿 | 73.88 | | 002519 | 银河电子 | 张 | 8.28 | ...

Core Points - Henan Xiangyu Medical Equipment Co., Ltd. has invested 5 million RMB to establish Tianjin Jiechuang Rui Intelligent Technology Co., Ltd., holding 100% of the shares [1] - Tianjin Jiechuang Rui Intelligent Technology Co., Ltd. was founded on July 31, 2025, with a registered capital of 5 million RMB and is located in Tianjin [2] Company Overview - The company operates in the computer, communication, and other electronic equipment manufacturing industry [1] - The legal representative of the company is Li Zhifeng [2] - The company engages in various services including AI application system integration, intelligent robot development and sales, wearable smart device manufacturing, and software development [2] Business Activities - The company is involved in the manufacturing and sales of first and second-class medical devices, as well as providing health consultation services [2] - It also offers technology services, including technical consultation, development, and transfer, as well as information technology consulting [2] - The company has a wide range of activities, including the sale of electronic components, industrial control computers, and general equipment manufacturing [2]

Core Viewpoint - Xiangyu Medical's stock closed at 44.97 yuan, down 2.24%, with a rolling PE ratio of 82.87 times, indicating a high valuation compared to the industry average [1][3]. Company Overview - Xiangyu Medical specializes in the research, production, and sales of rehabilitation medical devices, offering over a thousand products across ten categories, including rehabilitation therapy, training, and assessment [2]. - The company has received multiple awards for its projects, including first prizes for various rehabilitation technology initiatives from different medical and scientific associations [2]. Financial Performance - In the first quarter of 2025, the company reported revenue of 186 million yuan, a year-on-year increase of 10.02%, while net profit was 22.95 million yuan, reflecting a decline of 41.26% [3]. - The gross profit margin for the company stood at 65.30% [3]. Market Position - Xiangyu Medical's PE ratio of 82.87 times is significantly higher than the industry average of 53.65 times and the median of 37.22 times, placing it at the 102nd position in the industry ranking [1][3]. - As of March 31, 2025, the number of shareholders increased to 5,895, with an average holding value of 352,800 yuan per shareholder [1].

翔宇医疗属于医疗器械板块，公司主营业务为医疗器械的研发、生产和销售。公司产品涵盖多个医疗领 域，包括康复医疗设备等。 截至2025年7月31日收盘，翔宇医疗股价报46.00元，较前一交易日下跌0.55元，跌幅1.18%。当日成交 量为49334手，成交金额达2.27亿元。 来源:金融界 风险提示：股市有风险，投资需谨慎。 从资金流向来看，翔宇医疗7月31日主力资金净流出2320.53万元，占流通市值的0.32%。近期医疗器械 行业受到政策关注，国家医保局新设多项医疗新技术相关价格项目，包括脑机接口等创新技术。 ...

7月30日，医疗器械行业下跌0.38%，今日主力资金流出4.36亿元，成分股41只上涨，56只下跌。 主力资金净流出居前的分别为诺唯赞（1345.21万元）、翔宇医疗（1328.4万元）、山东药玻（1264.96 万元）、ST凯利（1228.57万元）、之江生物（1055.64万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300869康泰医学20.489.647210.99万元7.05%2300760 迈瑞医疗237.962.655584.03万元1.73%3002432九安医疗39.41.184117.95万元9.47%4600587新华医疗 16.813.382981.82万元5.89%5688050爱博医疗77.471.552538.28万元5.85%6300314戴维医疗 14.652.092318.76万元5.67%7300453三鑫医疗8.851.491781.91万元11.83%8300677英科医疗 33.965.51375.80万元1.21%9688029南微医学84.90.981371.50万元3.24%10300529健帆生物 24.370.911339.14万元2.86% 来 ...

Group 1 - The company has completed the non-trading transfer of shares under its 2025 Employee Stock Ownership Plan (ESOP), with 165 employees participating and a total subscription amount of 48.958 million yuan, corresponding to 1.883 million shares [1][2] - The shares were transferred at a price of 26.00 yuan per share, representing 1.1769% of the company's total share capital [2] - The ESOP has a duration of 36 months and a lock-up period of 12 months, starting from the date of the last share transfer to the ESOP account [2]

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-041 本公告披露日，公司本员工持股计划证券账户持有的公司股份数量为 188.30 万 股，占公司目前总股本的比例为 1.1769%。 根据本员工持股计划的相关规定，本员工持股计划的存续期为 36 个月、所 获标的股票的锁定期为 12 个月，均自公司公告最后一笔标的股票过户至本员工 持股计划名下之日起算。锁定期满后，在满足相关考核条件的前提下，一次性解 锁本员工持股计划相应标的股票。 公司将持续关注本员工持股计划的实施进展情况，并按照相关法律法规的规 定及时履行信息披露义务。敬请广大投资者注意投资风险。 河南翔宇医疗设备股份有限公司 关于 2025 年员工持股计划非交易过户完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 河南翔宇医疗设备股份有限公司（以下简称"公司"）分别于 2025 年 6 月 12 日、2025 年 7 月 1 日召开第三届董事会第五次会议、第三届监事会第五次会 议及 2025 年第一次临时股东大会，审议通过了《关于<公司 20 ...

Group 1 - Henan Xiangyu Medical Equipment Co., Ltd. has invested 10 million RMB to establish Yuanshu Intelligent Medical Equipment (Chongqing) Co., Ltd., holding 100% of the shares [1] - Yuanshu Intelligent Medical Equipment (Chongqing) Co., Ltd. was established on July 20, 2025, with a registered capital of 10 million RMB and is located in Chongqing [2] - The company is involved in the manufacturing of specialized medical equipment and has various permitted projects including the production and operation of second and third-class medical devices, as well as internet information services [2] Group 2 - The company’s business scope includes wearable smart device manufacturing, sales of second-class medical devices, and various technology services such as technical development and consultation [2] - Additional activities include the research and development of artificial intelligence applications, smart robots, and the provision of health consultation services [2] - The company is also engaged in the manufacturing and sales of electronic measuring instruments, as well as the rental of first and second-class medical devices [2]

Core Viewpoint - Xiangyu Medical's stock closed at 45.46 yuan, down 1.60%, with a rolling PE ratio of 83.78 times, indicating a high valuation compared to the industry average [1]. Company Overview - Xiangyu Medical specializes in the research, production, and sales of rehabilitation medical devices, offering over a thousand products across ten categories, including rehabilitation therapy, training, and assessment [2]. - The company has received multiple awards for its projects, including first prizes for various rehabilitation technology initiatives from different medical and scientific associations [2]. Financial Performance - In the first quarter of 2025, the company reported revenue of 186 million yuan, a year-on-year increase of 10.02%, while net profit was 22.95 million yuan, reflecting a decline of 41.26% [3]. - The gross profit margin for the company stood at 65.30% [3]. Industry Comparison - The average PE ratio for the medical device industry is 53.52 times, with a median of 37.14 times, positioning Xiangyu Medical at a significantly higher valuation compared to its peers [1][3]. - The company ranks 102nd in terms of PE ratio within the industry [1].